Yong Ben

1.5k total citations · 1 hit paper
28 papers, 1.2k citations indexed

About

Yong Ben is a scholar working on Oncology, Surgery and Pulmonary and Respiratory Medicine. According to data from OpenAlex, Yong Ben has authored 28 papers receiving a total of 1.2k indexed citations (citations by other indexed papers that have themselves been cited), including 19 papers in Oncology, 9 papers in Surgery and 8 papers in Pulmonary and Respiratory Medicine. Recurrent topics in Yong Ben's work include Cancer Immunotherapy and Biomarkers (14 papers), Bladder and Urothelial Cancer Treatments (9 papers) and Pancreatic and Hepatic Oncology Research (5 papers). Yong Ben is often cited by papers focused on Cancer Immunotherapy and Biomarkers (14 papers), Bladder and Urothelial Cancer Treatments (9 papers) and Pancreatic and Hepatic Oncology Research (5 papers). Yong Ben collaborates with scholars based in United States, United Kingdom and Canada. Yong Ben's co-authors include Xiaoping Jin, Ashok Gupta, Joyce Antal, Jingsong Zhang, Peter H. O’Donnell, Jae‐Lyun Lee, Terence W. Friedlander, Christopher Hoimes, Christophe Massard and Noah M. Hahn and has published in prestigious journals such as Journal of Clinical Oncology, PLoS ONE and Cancer Research.

In The Last Decade

Yong Ben

28 papers receiving 1.2k citations

Hit Papers

Efficacy and Safety of Durvalumab in Locally Advanced or ... 2017 2026 2020 2023 2017 200 400 600
What are hit papers?

Hit papers significantly outperform the citation benchmark for their cohort. A paper qualifies if it has ≥500 total citations, achieves ≥1.5× the top-1% citation threshold for papers in the same subfield and year (this is the minimum needed to enter the top 1%, not the average within it), or reaches the top citation threshold in at least one of its specific research topics.

  1. Efficacy and Safety of Durvalumab in Locally Advanced or Metastatic Urothelial Carcinoma
    2017 664 citations Thomas Powles, Peter H. O’Donnell et al. JAMA Oncology profile →

Peers — A (Enhanced Table)

Peers by citation overlap · career bar shows stage (early→late) cites · hero ref

Name h Career Trend Papers Cites
Yong Ben United States 15 848 510 238 202 186 28 1.2k
Hao-Yuan Mo China 17 667 0.8× 352 0.7× 188 0.8× 254 1.3× 388 2.1× 34 1.3k
Francesca Negri Italy 21 1.0k 1.2× 303 0.6× 273 1.1× 422 2.1× 394 2.1× 61 1.7k
Keiji Kato Japan 17 229 0.3× 279 0.5× 135 0.6× 324 1.6× 352 1.9× 46 988
Hongfen Lu China 18 414 0.5× 229 0.4× 87 0.4× 202 1.0× 196 1.1× 45 930
Shivan Sivakumar United Kingdom 15 643 0.8× 146 0.3× 135 0.6× 355 1.8× 317 1.7× 40 1.0k
Oskar Koperek Austria 24 314 0.4× 404 0.8× 45 0.2× 140 0.7× 299 1.6× 44 1.3k
Runbo Zhong China 18 715 0.8× 101 0.2× 248 1.0× 440 2.2× 275 1.5× 89 1.1k
Guoxu Fang China 6 904 1.1× 285 0.6× 57 0.2× 84 0.4× 835 4.5× 16 1.3k
Kris Persaud United States 15 800 0.9× 182 0.4× 127 0.5× 88 0.4× 771 4.1× 20 1.3k
Vadim S. Koshkin United States 18 544 0.6× 670 1.3× 92 0.4× 483 2.4× 335 1.8× 118 1.3k

Countries citing papers authored by Yong Ben

Since Specialization
Citations

This map shows the geographic impact of Yong Ben's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Yong Ben with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Yong Ben more than expected).

Fields of papers citing papers by Yong Ben

Since Specialization
Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Yong Ben. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Yong Ben. The network helps show where Yong Ben may publish in the future.

Co-authorship network of co-authors of Yong Ben

This figure shows the co-authorship network connecting the top 25 collaborators of Yong Ben. A scholar is included among the top collaborators of Yong Ben based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Yong Ben. Yong Ben is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

20 of 20 papers shown
1.
Zając, M, Jiabu Ye, Pralay Mukhopadhyay, et al.. (2020). Optimal PD-L1–high cutoff for association with overall survival in patients with urothelial cancer treated with durvalumab monotherapy. PLoS ONE. 15(4). e0231936–e0231936. 16 indexed citations
2.
Zając, Magdalena, Anne-Marie Boothman, Yong Ben, et al.. (2018). Analytical Validation and Clinical Utility of an Immunohistochemical Programmed Death Ligand-1 Diagnostic Assay and Combined Tumor and Immune Cell Scoring Algorithm for Durvalumab in Urothelial Carcinoma. Archives of Pathology & Laboratory Medicine. 143(6). 722–731. 18 indexed citations
3.
Sharma, Padmanee, Luc Dirix, Filip De Vos, et al.. (2018). Efficacy and tolerability of tremelimumab in patients with metastatic pancreatic ductal adenocarcinoma.. Journal of Clinical Oncology. 36(4_suppl). 470–470. 20 indexed citations
4.
Sharp, Leslie L., Cathy Chang, Gerhard Frey, et al.. (2018). Abstract 827: Anti-tumor efficacy of BA3011, a novel Conditionally Active Biologic (CAB) anti-AXL-ADC. Cancer Research. 78(13_Supplement). 827–827. 16 indexed citations
5.
Rodón, Jordi, Matthew H. Taylor, Eileen M. O’Reilly, et al.. (2018). A phase 1/2 dose-escalation and expansion study of a conditionally active anti-AXL humanized monoclonal antibody (BA3011) in patients with advanced solid tumors.. Journal of Clinical Oncology. 36(15_suppl). TPS12126–TPS12126. 14 indexed citations
6.
Ye, Jiabu, Pralay Mukhopadhyay, Xiaoping Jin, et al.. (2018). Optimization of PD-L1 algorithm for predicting overall survival (OS) in patients with urothelial cancer (UC) treated with durvalumab monotherapy.. Journal of Clinical Oncology. 36(15_suppl). 4530–4530. 1 indexed citations
7.
Sharp, Leslie L., Cathy Chang, Gerhard Frey, et al.. (2018). Abstract 833: Anti-tumor efficacy of BA3021, a novel Conditionally Active Biologic (CAB) anti-ROR2 ADC. Cancer Research. 78(13_Supplement). 833–833. 15 indexed citations
8.
Baverel, Paul, Yanan Zheng, Xuyang Song, et al.. (2017). Population Pharmacokinetics of Durvalumab in Cancer Patients and Association With Longitudinal Biomarkers of Disease Status. Clinical Pharmacology & Therapeutics. 103(4). 631–642. 112 indexed citations
9.
Powles, Thomas, Paul Baverel, Rajesh Narwal, et al.. (2017). Tumor shrinkage and increased overall survival are associated with improved albumin, neutrophil lymphocyte ratio (NLR) and decreased durvalumab clearance in NSCLC and UC patients receiving durvalumab.. Journal of Clinical Oncology. 35(15_suppl). 3035–3035. 9 indexed citations
10.
Powles, Thomas, Peter H. O’Donnell, Christophe Massard, et al.. (2017). Efficacy and Safety of Durvalumab in Locally Advanced or Metastatic Urothelial Carcinoma. JAMA Oncology. 3(9). e172411–e172411. 664 indexed citations breakdown →
11.
Bais, Carlos, Michael Kuziora, Chris Morehouse, et al.. (2017). Biologic and clinical relevance of an IFNG mRNA signature (IFNGS) and PD-L1 protein expression in tumor and immune cells in urothelial cancer (UC) patients (pts) treated with durvalumab (D).. Journal of Clinical Oncology. 35(15_suppl). 3037–3037. 8 indexed citations
12.
O’Reilly, Eileen M., Do‐Youn Oh, Myung Ah Lee, et al.. (2016). A phase 2, open-label, multicenter study of durvalumab (MEDI4736) ± tremelimumab in patients (pts) with metastatic pancreatic ductal adenocarcinoma (mPDAC): ALPS.. Journal of Clinical Oncology. 34(15_suppl). TPS4150–TPS4150. 3 indexed citations
13.
Zhou, Xiaofei, et al.. (2013). Abstract B216: Mass balance, routes of excretion and pharmacokinetics of investigational oral [14C]alisertib (MLN8237) in patients with advanced solid tumors or lymphoma.. Molecular Cancer Therapeutics. 12(11_Supplement). B216–B216. 4 indexed citations
14.
Qin, Shukui, Feng Bi, Ying Cheng, et al.. (2012). Axitinib versus sorafenib as second‑line therapy in Asian patients with metastatic renal cell carcinoma (mRCC): Results from a registrational study.. Journal of Clinical Oncology. 30(18_suppl). LBA4537–LBA4537. 2 indexed citations
15.
Chen, Ling-chun, et al.. (2004). Temporal gene expression patterns in G93A/SOD1 mouse. Amyotrophic Lateral Sclerosis and Other Motor Neuron Disorders. 5(3). 164–171. 23 indexed citations
16.
Dairkee, Shanaz H., Youngran Ji, Yong Ben, et al.. (2004). A molecular 'signature' of primary breast cancer cultures; patterns resembling tumor tissue. BMC Genomics. 5(1). 47–47. 46 indexed citations
17.
Ben, Yong, Andrew P. Smith, Peter W. Schiller, & Nancy M. Lee. (2004). Tolerance develops in spinal cord, but not in brain with chronic [Dmt1]DALDA treatment. British Journal of Pharmacology. 143(8). 987–993. 10 indexed citations
18.
Meng, Zhen, Yong Ben, Zheng Li, et al.. (2004). Aberrations of breast cancer susceptibility genes occur early in sporadic breast tumors and in acquisition of breast epithelial immortalization. Genes Chromosomes and Cancer. 41(3). 214–222. 15 indexed citations
19.
Riba, Pál, Yong Ben, Andrew Smith, Susanna Fürst, & Nancy M. Lee. (2002). Morphine Tolerance in Spinal Cord Is Due to Interaction between μ- and δ-Receptors. Journal of Pharmacology and Experimental Therapeutics. 300(1). 265–272. 33 indexed citations
20.
Riba, Pál, Yong Ben, Thi M.‐D. Nguyen, et al.. (2002). [Dmt¹]DALDA is Highly Selective and Potent at μ Opioid Receptors, but is not Cross-Tolerant with Systemic Morphine. Current Medicinal Chemistry. 9(1). 31–39. 28 indexed citations

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact

Breakdown of academic impact, for papers by Hao-Yuan Mo Breakdown of academic impact, for papers by Francesca Negri Breakdown of academic impact, for papers by Keiji Kato Breakdown of academic impact, for papers by Hongfen Lu Breakdown of academic impact, for papers by Shivan Sivakumar Breakdown of academic impact, for papers by Oskar Koperek Breakdown of academic impact, for papers by Runbo Zhong Breakdown of academic impact, for papers by Guoxu Fang Breakdown of academic impact, for papers by Kris Persaud Breakdown of academic impact, for papers by Vadim S. Koshkin
Rankless by CCL
2026